期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

9型前蛋白转化酶枯草杆菌蛋白酶/kexin抑制药在调脂治疗中的应用进展 被引量：3

Advances of using proprotein convertase subtilisin/kexin type 9 inhibitor in treatment of dyslipidemia
原文传递
导出
摘要 9型前蛋白转化酶枯草杆菌蛋白酶/kexin(PCSK9)抑制药通过抑制低密度脂蛋白受体的降解,发挥重要的调脂作用。在PCSK9抑制药中,PCSK9单克隆抗体是研究最多、疗效最稳定的药物。alirocumab、evolocumab和bococizumab是研究和应用最多的PCSK9单克隆抗体。上述药物在单独使用、和他汀类药物合用以及用于他汀类药物不耐受者、家族性高胆固醇血症等的调脂治疗中发挥重要作用。 Proprotein convertase subtilisin/kexin type 9（PCSK9） inhibitor plays an important role in the treatment of dyslipidemia through inhibiting the degradation of low- density lipoprotein receptor. Among PCSK9 inhibitor, PCSK9 monoclonal antibodies are mostly studied and have stable efficacy. Alirocumab, evolocumab and bococizumab have been mostly researched and applied. These drugs play important roles in the treatment of dyslipidemia with monotherapy, combination with statins, for statin intolerance, and in familial hypercholes-terolemia patients.
作者 黄震华
机构地区 上海交通大学医学院附属第九人民医院心血管病研究室
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2016年第4期237-242,共6页 Chinese Journal of New Drugs and Clinical Remedies
关键词 前蛋白转化酶类 血脂异常 胆固醇 LDL 低密度脂蛋白受体 proprotein convertases dyslipidemia cholesterol LDL low-density lipoprotein receptor
分类号 R972.6 [医药卫生—药品]
  • 相关文献

参考文献24

  • 1URBAN D,POSS J,BOHN M,et al.Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis[J].J Am Coll Cardiol,2013,62(16):1401-1408.
  • 2RASHID S,CURTIS DE,GARUTI R,et al.Decreased plasma cholesterol and hypersensitivity to statins in mice laching PCSK 9[J].Proc Natl Acad Sci USA,2005,102(15):5374-5379.
  • 3ZHANG Y,EIGENBROT C,ZHOU L,et al.Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor[J].J Biol Chem,2014,289(2):942-955.
  • 4SEIDAH NG,PRAT A.The biology and therapeutic targeting of the proprotein convertases[J].Nat Rev Drug Discov,2012,11(5):367-383.
  • 5STEIN EA,GIPE D,BERGERON J,et al.Effect of a monoclonal antibody to PCSK9,REGN 727/SAR 236553,to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy:a phase 2 randomised controlled trial[J].Lancet,2012,380(9836):29-36.
  • 6LUNVEN C,PAEHLER T,POITIERS F,et al.A randomized study of the relative pharmacokinetics,pharmacodynamics,and safety of alirocumab,a fully human monoclonal antibody to PCSK9,after single subcutaneous administration at three different injection sites in healthy subjects[J].Cardiovasc Ther,2014,32(6):297-301.
  • 7DIAS CS,SHAYWITZ AJ,WASSERMAN SM,et al.Effects of AMG 145 on low-density lipoprotein cholesterol levels:results from 2 randomized,double-blind,placebo-controlled,ascendingdose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins[J].J Am Coll Cardiol,2012,60(19):1888-1898.
  • 8BALLANTYNE CM,NEUTEL J,CROPP A,et al.Results of bococizumab,a monoonal antibody against proprotein convertase subtilisin/kexin type 9,from a randomized,placebo-controlled,dose-ranging study in statin-treated subjects with hypercholesterolemia[J].Am J Cardiol,2015,115(9):1212-1221.
  • 9GIUGLIANO RP,SABATINE MS.Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?[J].J Am Coll Cardiol,2015,65(24):2638-2651.
  • 10KOREN MJ,LUNDQVIST P,BOLOGNESE M,et al.AntiPCSK9 monotherapy for hypercholesterolemia:the MENDEL-2randomized,controlled phaseⅢclinical trial of evolocumab[J].J Am Coll Cardiol,2014,63(23):2531-2540.

同被引文献7

引证文献3

二级引证文献2

中国新药与临床杂志
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部